Collaboration, License, and Other Agreements - Checkmate Narrative (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended	9 Months Ended
	May 31, 2022	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Acquired in-process research and development in connection with asset acquisition			$ 0.0	$ 195.0
Asset acquisition, cash and cash equivalents acquired		$ 26.4
Checkmate Pharmaceuticals, Inc.
Disaggregation of Revenue [Line Items]
Asset acquisition, consideration transferred	$ 250.0
Acquired in-process research and development in connection with asset acquisition		195.0
Asset acquisition, assets acquired and liabilities assumed, net		$ 61.7